Investigative Ophthalmology & Visual Science, Vol 37, 2426-2433, Copyright © 1996 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Cultured human trabecular meshwork cells express functional alpha 2A adrenergic receptors

WD Stamer, Y Huang, RE Seftor, SS Svensson, RW Snyder and JW Regan
Department of Pharmacology/Toxicology, University of Arizona, Tucson 85721, USA.

PURPOSE: For the treatment of glaucoma, alpha-2 adrenergic receptor (alpha 2-AR) agonists are thought to lower intraocular pressure primarily by decreasing aqueous humor production. Effects on the outflow pathways, however, also may occur. To begin to examine this possibility, the authors characterized the alpha 2-AR subtypes present in cultures of human trabecular meshwork (HTM) cells using both immunofluorescence microscopy and functional measures of alpha 2-AR activation. METHODS: For immunofluorescence microscopy, subtype- specific polyclonal antibodies that recognize each of the human alpha 2- AR subtypes (alpha 2A, alpha 2B, alpha 2C) were used. Functional studies involved the inhibition of forskolin-stimulated cyclic adenosine monophosphate (cAMP) production, the stimulation of mitogen- activated protein (MAP) kinase activity, and the stimulation of mitotic activity as reflected by the expression of proliferating cell nuclear antigen (PCNA). RESULTS: From the immunofluorescence microscopy, there was evidence for the presence of the alpha 2A subtype, but not alpha 2B or alpha 2C subtype, on HTM cells. The administration of the alpha 2- agonist, dexmedetomidine, to HTM cells resulted in a 90% inhibition of forskolin-stimulated cAMP formation, a twofold stimulation of MAP kinase activity, and a threefold increase in the expression of PCNA. Additionally, preincubation of cells with either of the alpha 2-AR- selective antagonists, rauwolscine or atipamezole, reversed the functional effects of dexmedetomidine. CONCLUSIONS: Functional alpha 2A- ARs are present on HTM cells where they may affect the outflow pathway during the treatment of glaucoma with alpha 2-AR agonists.

This article has been cited by other articles:

				F. W. Rozsa, K. Scott, H. Pawar, S. Moroi, and J. E. Richards Effects of Timolol on MYOC, OPTN, and WDR36 RNA Levels Arch Ophthalmol, January 1, 2008; 126(1): 86 - 93. [Abstract] [Full Text] [PDF]

				F B Kalapesi, M T Coroneo, and M A Hill Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection Br. J. Ophthalmol., June 1, 2005; 89(6): 758 - 763. [Abstract] [Full Text] [PDF]

				C. H. Mitchell, J. C. Fleischhauer, W. D. Stamer, K. Peterson-Yantorno, and M. M. Civan Human trabecular meshwork cell volume regulation Am J Physiol Cell Physiol, July 1, 2002; 283(1): C315 - C326. [Abstract] [Full Text] [PDF]

				J. Benozzi, C. O. Jaliffa, F. F. Lacoste, D. W. Llomovatte, M. I. K. Sarmiento, and R. E. Rosenstein Effect of Brimonidine on Rabbit Trabecular Meshwork Hyaluronidase Activity Invest. Ophthalmol. Vis. Sci., July 1, 2000; 41(8): 2268 - 2272. [Abstract] [Full Text]

				D. B. Bylund and D. M. Chacko Characterization of {alpha}2 Adrenergic Receptor Subtypes in Human Ocular Tissue Homogenates Invest. Ophthalmol. Vis. Sci., September 1, 1999; 40(10): 2299 - 2306. [Abstract] [Full Text] [PDF]

				A. J. Maniotis, R. Folberg, A. Hess, E. A. Seftor, L. M.G. Gardner, J. Pe'er, J. M. Trent, P. S. Meltzer, and M. J. C. Hendrix Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry Am. J. Pathol., September 1, 1999; 155(3): 739 - 752. [Abstract] [Full Text] [PDF]

				W. D. Stamer, B. C. Roberts, and D. L. Epstein Hydraulic Pressure Stimulates Adenosine 3',5'-Cyclic Monophosphate Accumulation in Endothelial Cells from Schlemm’s Canal Invest. Ophthalmol. Vis. Sci., August 1, 1999; 40(9): 1983 - 1988. [Abstract] [Full Text] [PDF]